Patents by Inventor Praveen Mudunuri

Praveen Mudunuri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10716789
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: July 21, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael P. Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20190038615
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 19, 2018
    Publication date: February 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nicolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Publication number: 20180325897
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 15, 2018
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Patent number: 10039761
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 7, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20180153874
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: July 6, 2017
    Publication date: June 7, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nicolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Patent number: 9856284
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: January 2, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Anuj K Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Patent number: 9771361
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 26, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
  • Publication number: 20160339024
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Application
    Filed: April 15, 2016
    Publication date: November 24, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20160318969
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Application
    Filed: July 14, 2016
    Publication date: November 3, 2016
    Inventors: Anuj K Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Publication number: 20160251353
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1).½H2O, Form F of HCl salt of Compound (1).3H2O, Form D of HCl salt of Compound (1), Form A of Compound (1), and Form A of tosylate salt of Compound (1). Such polymorphic forms are employed for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Inventors: Kwame W. Nti-Addae, Michael Waldo, Simon Adam O'Neil, John Gregg Van Alsten, Dainius Macikenas, Praveen Mudunuri, Yi Shi, Mark Willem Ledeboer, Valdas Jurkauskas, Ales Medek, Steven Jones, Randal Byrn, Mohammed Asmal, Sarah Marie Robertson, Wanjung Tsai
  • Patent number: 9394330
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: July 19, 2016
    Assignee: Alios BioPharma, Inc.
    Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Publication number: 20160067239
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: January 23, 2015
    Publication date: March 10, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Publication number: 20160022665
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: January 28, 2016
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Publication number: 20150175647
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Application
    Filed: December 22, 2014
    Publication date: June 25, 2015
    Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Publication number: 20150164883
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formulas I and II, optionally in combination with a Compound of Formula III and/or a Compound of Formula IV. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 25, 2015
    Publication date: June 18, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Hayley Marie Binch, Martyn Curtis Botfield, Lev Tyler Dewey Fanning, Peter Diederik Jan Grootenhuis, Dennis James Hurley, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ritu Rohit Kaushik, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Brian Luisi, Ales Medek, Praveen Mudunuri, Mehdi Numa, Urvi Jagdishbhai Sheth, Alina Silina, Mark Jeffrey Sullivan, Marinus Jacobus Verwijs, Xiaoqing Yang, Christopher Ryan Young, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokmik
  • Publication number: 20150141459
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nikolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Patent number: 8916538
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: December 23, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
  • Publication number: 20140329855
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 6, 2014
    Inventors: Sneha G. Arekar, Steven C. Johnston, Mariusz Krawiec, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan
  • Patent number: 8785476
    Abstract: The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: July 22, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sneha G. Arekar, Steven C. Johnston, Mariusz Krawiec, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan
  • Publication number: 20140154210
    Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
    Type: Application
    Filed: March 11, 2013
    Publication date: June 5, 2014
    Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent